2639 Results

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Younes
    Younes
  7. Matasar
    Matasar
  8. Moskowitz
    Moskowitz
  9. Yahalom
    Yahalom
  10. Portlock
    Portlock

Groups

  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)
  7. Executive Committee, Center for Hematologic Malignancies (389)
  8. Epidemiology and Biostatistics (363)
  9. GSK Faculty (356)
  10. Department of Pathology and Laboratory Medicine (300)
  1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T‐cell lymphoma with less than 10% CD30 expression (SGN35‐032, trial in progress)
    Meeting Abstract

    Jagadeesh, D.; Knowles, S.; Horwitz, S. M.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes in later‐lines of therapy for relapsed/refractory follicular lymphoma: Results from the international SCHOLAR‐5 study
    Meeting Abstract

    Ghione, P.; Ghesquieres, H.; Bobillo, S.; Patel, A. R.; Kanters, S.; Deighton, K.; Dong, H.; Yang, Y.; Ma, L.; Limbrick‐Oldfield, E. H.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 ECHELON‐1 study
    Meeting Abstract

    Crosswell, H. E.; LaCasce, A. S.; Bartlett, N. L.; Straus, D. J.; Savage, K. J.; Zinzani, P. L.; Collins, G. P.; Fanale, M. A.; Fenton, K.; Dong, C.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of adult lymphoma‐associated hemophagocytic lymphohistiocytosis (HLH)
    Meeting Abstract

    Lee, C. Y.; Wills Sanin, B.; Vardhana, S. A.; Moskowitz, A. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Journal Article

    Hamadani, M.; Collins, G. P.; Caimi, P. F.; Samaniego, F.; Spira, A.; Davies, A.; Radford, J.; Menne, T.; Karnad, A.; Zain, J. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
    Journal Article

    Straus, D. J.; Długosz-Danecka, M.; Connors, J. M.; Alekseev, S.; Illés, Á; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
    Journal Article

    Bobillo, S.; Joffe, E.; Sermer, D.; Mondello, P.; Ghione, P.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; more...
    Blood Cancer Journal (2021)

    Fulltext@MSK | Save
  • CheckMate 436: Primary efficacy and safety analysis of the phase 2 study evaluating nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma
    Meeting Abstract

    Santoro, A.; Moskowitz, A.; Ferrari, S.; Carlo-Stella, C.; Collins, G.; Fanale, M.; Francis, S.; Sacchi, M.; Savage, K.
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Eyre, T.; Shah, N. N.; Alencar, A.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save